TABLE 2.
Hazard Ratios for Overall Survival for Study Treatment Groups
| Unadjusted | Adjusted | Propensity Score Adjusted | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | HR | 95% CI | P Value | HR | 95% CI | P Value | HR | 95% CI | P Value |
| Treatment group | |||||||||
| Doublets | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – |
| Pem-based | 0.96 | 0.84-1.11 | 0.602 | 0.98 | 0.84-1.13 | 0.754 | 1.04 | 0.90-1.20 | 0.590 |
| Pem+Bev-based | 0.48 | 0.32-0.72 | 0.001 | 0.50 | 0.33-0.76 | 0.001 | 0.63 | 0.42-0.94 | 0.023 |
| Bev-based | 0.85 | 0.71-1.01 | 0.066 | 0.97 | 0.81-1.16 | 0.741 | 1.04 | 0.88-1.24 | 0.653 |
| Singlets | 1.55 | 1.26-1.89 | < 0.001 | 1.53 | 1.25-1.87 | < 0.001 | 1.50 | 1.22-1.84 | <0.001 |
| TKI | 0.88 | 0.78-1.00 | 0.045 | 0.85 | 0.74-0.98 | 0.028 | 0.83 | 0.73-0.94 | 0.004 |
| Age, years | |||||||||
| < 65 | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – | |||
| ≥ 65 | 1.00 | 0.91-1.11 | 0.947 | 0.98 | 0.89-1.08 | 0.674 | |||
| Gender | |||||||||
| Female | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – | |||
| Male | 1.11 | 1.00-1.22 | 0.045 | 1.09 | 0.99-1.20 | 0.071 | |||
| Race | |||||||||
| White | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – | |||
| Black | 0.95 | 0.82-1.11 | 0.538 | 0.90 | 0.77-1.04 | 0.146 | |||
| Asian | 0.89 | 0.77-1.03 | 0.131 | 0.92 | 0.80-1.06 | 0.231 | |||
| Hispanic | 0.89 | 0.75-1.06 | 0.202 | 0.88 | 0.74-1.04 | 0.133 | |||
| Other/unknown | 1.05 | 0.66-1.65 | 0.843 | 1.03 | 0.65-1.63 | 0.891 | |||
| Region | |||||||||
| North | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – | |||
| South | 1.01 | 0.92-1.12 | 0.803 | 1.09 | 0.99-1.20 | 0.091 | |||
| AJCC stage | |||||||||
| IIIB | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – | |||
| IV | 1.78 | 1.56-2.04 | < 0.001 | 1.86 | 1.62-2.14 | < 0.001 | |||
| Histology | |||||||||
| Nonsquamous | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – | |||
| Squamous | 1.07 | 0.94-1.23 | 0.319 | 1.19 | 1.04-1.35 | 0.010 | |||
| Subsequent therapy | |||||||||
| No | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – | |||
| Yes | 0.50 | 0.45-0.55 | < 0.001 | 0.44 | 0.40-0.49 | < 0.001 | |||
| Charlson score | 1.04 | 1.01-1.07 | 0.019 | 1.04 | 1.01-1.07 | 0.021 | |||
| Smoking status | |||||||||
| Past | 1.0 [Ref] | 1.0 [Ref] | – | 1.0 [Ref] | 1.0 [Ref] | – | |||
| Current | 1.13 | 0.96-1.33 | 0.129 | 1.09 | 0.93-1.29 | 0.280 | |||
| Never | 0.89 | 0.78-1.01 | 0.069 | 0.93 | 0.82-1.05 | 0.249 | |||
AJCC = American Joint Committee on Cancer; Bev = bevacizumab; CI = confidence interval; HR = hazard ratio; Pem = pemetrexed; Ref = reference group; SD = standard deviation; TKI = tyrosine-kinase inhibitor.